Clinical Safety

The journey of developing groundbreaking cancer therapies is fraught with challenges and triumphs, and the clinical trial of BNT326/YL202 by BioNTech and MediLink Therapeutics is no exception. This antibody-drug conjugate (ADC) candidate has shown promise in treating non-small cell lung cancer and

In an impressive turn of events, the U.S. Food and Drug Administration (FDA) has lifted the partial hold on BioNTech and MediLink Therapeutics' clinical trial for their groundbreaking Antibody-Drug Conjugate (ADC) candidate BNT326/YL202. Originally put on hold due to serious safety concerns,

The latest findings from Kiromic BioPharma’s phase 1/2 clinical trial spotlight the promising potential of its investigational therapy, Deltacel (KB-GDT-01), an allogeneic gamma delta T-cell (GDT) therapy. This novel therapy is being evaluated for patients with non-small cell lung cancer (NSCLC) w

The landscape of medical treatment and drug development is experiencing a new dawn as the U.S. Food and Drug Administration (FDA) plays a pivotal role in ushering in an era where the once unimaginable becomes reality. With a discerning eye on cutting-edge therapies, especially in gene therapy and

The healthcare sector grapples with protecting patient data amidst a surge of cyber threats. The 2024 Security Culture Report by KnowBe4 casts light on the defensive measures taken by healthcare and pharmaceutical industries to combat these risks. It assesses the effectiveness of their security

The skyrocketing trend of medical tourism is reshaping the pursuit of wellness as individuals globally seek top-notch yet cost-effective healthcare coupled with the experience of foreign cultures. This industry is flourishing, propelled by its alluring combination of lower costs, superior medical